Isolation and purification of oligopeptides from Ruditapes philippinarum and its inhibition on the growth of DU‑145 cells in vitro

Yang,Zuisu; Zhao,Yuqin; Yan,Haiqiang; Xu,Lv; Ding,Guofang; Yu,Di; Sun,Yu

doi:10.3892/mmr.2014.2788

Isolation and purification of oligopeptides from Ruditapes philippinarum and its inhibition on the growth of DU‑145 cells in vitro

Authors:
- Zuisu Yang
- Yuqin Zhao
- Haiqiang Yan
- Lv Xu
- Guofang Ding
- Di Yu
- Yu Sun
View Affiliations

Affiliations: School of Food Science and Pharmacy, Zhejiang Provincial Key Engineering Technology Research Center of Marine Biomedical Products, Zhejiang Ocean University, Zhoushan, Zhejiang 316000, P.R. China
Published online on: October 27, 2014 https://doi.org/10.3892/mmr.2014.2788
Pages: 1063-1068

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Ruditapes philippinarum is a member of the Veneridae family of marine bivalve molluscs. RPOI‑1 (Ruditapes philippinarum oligopeptide) is a tetrapeptide that can be extracted from Ruditapes philippinarum by means of enzymolysis. This study showed that RPOI‑1 strongly inhibits proliferation and induces apoptosis in DU‑145 human prostate cancer cells. When cells were treated with varying concentrations of RPOI‑1, significant inhibition of proliferation was detected by an MTT assay, and sub‑G1 and G2/M phase cell cycle arrest was observed using flow cytometric (FCM) analysis. Furthermore, morphological changes characteristic of apoptosis and an increase in the proportion of apoptotic cells were observed using double sequential acridine orange/ethidium bromide staining, FCM analysis and transmission election microscopy. FCM studies showed that exposing DU‑145 cells to 10, 20 and 30 mg/ml RPOI‑1 for 24 h increased the percentage of cells in the early‑stages of apoptotis in a dose‑dependent manner, with the numbers rising from 3.01% in the control group to 13.40% in the group treated with the highest dose.

View Figures

View References

1	Goel S, Mita AC, Mita M, et al: A phase I study of eribulin mesylate (E7389), a mechanistically novel inhibitor of microtubule dynamics, in patients with advanced solid malignancies. Clin Cancer Res. 15:4207–4212. 2009. View Article : Google Scholar : PubMed/NCBI
2	Hadaschik BA, Adomat H, Fazli L, et al: Intravesical chemotherapy of high-grade bladder cancer with HTI-286, a synthetic analogue of the marine sponge product hemiasterlin. Clin Cancer Res. 14:1510–1518. 2008. View Article : Google Scholar : PubMed/NCBI
3	Den Brok MW, Nuijen B, Meijer DM, Millán E, Manada C and Beijnen JH: Pharmaceutical development of a parenteral lyophilised formulation of the investigational anticancer agent ES-285. HCl PDA J Pharm Sci Technol. 59:246–257. 2005.
4	Garg V, Zhang W, Gidwani P, Kim M and Kolb EA: Preclinical analysis of tasidotin HCl in Ewing’s sarcoma, rhabdomyosarcoma, synovial sarcoma, and osteosarcoma. Clin Cancer Res. 13:5446–5454. 2007. View Article : Google Scholar : PubMed/NCBI
5	Huang F, Yang Z, Yu D, Wang J, Li R and Ding G: Sepia ink oligopeptide induces apoptosis in prostate cancer cell lines via caspase-3 activation and elevation of Bax/Bcl-2 ratio. Mar Drugs. 10:2153–2165. 2012. View Article : Google Scholar : PubMed/NCBI
6	Sánchez C, Mendoza P, Contreras HR, et al: Expression of multidrug resistance proteins in prostate cancer is related with cell sensitivity to chemotherapeutic drugs. Prostate. 69:1448–1459. 2009. View Article : Google Scholar : PubMed/NCBI
7	Nehmé A, Varadarajan P, Sellakumar G, et al: Modulation of docetaxel-induced apoptosis and cell cycle arrest by all- trans retinoic acid in prostate cancer cells. Br J Cancer. 84:1571–1576. 2001. View Article : Google Scholar : PubMed/NCBI
8	Tyagi AK, Singh RP, Agarwal C, Chan DC and Agarwal R: Silibinin strongly synergizes human prostate carcinoma DU145 cells to doxorubicin-induced growth inhibition, G2-M arrest, and apoptosis. Clin Cancer Res. 8:3512–3519. 2002.PubMed/NCBI
9	Dong H, Bai LP, Wong VK, et al: The in vitro structure-related anti-cancer activity of ginsenosides and their derivatives. Molecules. 16:10619–10630. 2011. View Article : Google Scholar : PubMed/NCBI
10	Sondhi SM, Singh J, Rani R, Gupta PP, Agrawal SK and Saxena AK: Synthesis, anti-inflammatory and anticancer activity evaluation of some novel acridine derivatives. Eur J Med Chem. 45:555–563. 2010. View Article : Google Scholar
11	Heo SJ, Kim KN, Yoon WJ, et al: Chromene induces apoptosis via caspase-3 activation in human leukemia HL-60 cells. Food Chem Toxicol. 49:1998–2004. 2011. View Article : Google Scholar : PubMed/NCBI
12	Bartek J, Lukas C and Lukas J: Checking on DNA damage in S phase. Nat Rev Mol Cell Biol. 5:792–804. 2004. View Article : Google Scholar : PubMed/NCBI
13	Kinloch RA, Treherne JM, Furness LM and Hajimohamadreza I: The pharmacology of apoptosis. Trends Pharmacol Sci. 20:35–42. 1999. View Article : Google Scholar : PubMed/NCBI
14	Dirsch VM, Antlsperger DS, Hentze H and Vollmar AM: Ajoene, an experimental anti-leukemic drug: mechanism of cell death. Leukemia. 16:74–83. 2002. View Article : Google Scholar : PubMed/NCBI
15	Gamet-Payrastre L, Li P, Lumeau S, et al: Sulforaphane, a naturally occurring isothiocyanate, induces cell cycle arrest and apoptosis in HT29 human colon cancer cells. Cancer Res. 60:1426–1433. 2000.PubMed/NCBI